T. Rowe Price Associates’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
|
|||||
|
2025
Q2 | $49K | Sell |
|
|||||
|
2025
Q1 | $111K | Sell |
|
|||||
|
2024
Q4 | $2.97M | Sell |
|
|||||
|
2024
Q3 | $3.82M | Buy |
|
|||||
|
2024
Q2 | $3.78M | Sell |
|
|||||
|
2024
Q1 | $55M | Buy |
|
|||||
|
2023
Q4 | $44M | Buy |
|
|||||
|
2023
Q3 | $54.5M | Buy |
|
|||||
|
2023
Q2 | $75.7M | Buy |
|
|||||
|
2023
Q1 | $37.8M | Buy |
|
|||||
|
2022
Q4 | $43.8M | Sell |
|
|||||
|
2022
Q3 | $48M | Sell |
|
|||||
|
2022
Q2 | $121M | Buy |
|
|||||
|
2022
Q1 | $194M | Sell |
|
|||||
|
2021
Q4 | $368M | Buy |
|
|||||
|
2021
Q3 | $249M | Buy |
|
|||||
|
2021
Q2 | $173M | Buy |
|
|||||
|
2021
Q1 | $47M | Sell |
|
|||||
|
2020
Q4 | $56.8M | Sell |
|
|||||
|
2020
Q3 | $36.2M | Sell |
|
|||||
|
2020
Q2 | $57M | Buy |
|